Insider Trading June 25, 2026 07:09 PM

Aditxt Shareholder Liquidates Entire Stake as Stock Plummets Amid Corporate Restructuring

Takeover Time 2026 LLC exits position entirely as ADTX trades near zero, coinciding with subsidiary SPAC plans and regulatory compliance milestones.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
ADTX

Takeover Time 2026 LLC, a significant ten percent shareholder of Aditxt, Inc. (NASDAQ:ADTX), has completely divested its holdings, selling 3,420,439 shares on June 23, 2026. This transaction occurs against a backdrop of severe stock devaluation, with the share price collapsing to $0.01 from a 52-week high of $117.84, resulting in a -100% year-to-date return. The sale, executed at $0.02 per share, leaves the entity with no remaining common stock in the company. This financial exit parallels a period of intense operational and structural changes at Aditxt, including the planned public listing of its subsidiary Ignite Proteomics LLC via a SPAC transaction valued at approximately $150 million, the appointment of Jeffrey M. Busch as interim CEO, and the successful navigation of Nasdaq listing compliance standards.

Aditxt Shareholder Liquidates Entire Stake as Stock Plummets Amid Corporate Restructuring
ADTX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Takeover Time 2026 LLC sold 3,420,439 shares at $0.02 per share, fully exiting its 10% stake in ADTX on June 23, 2026.
  • Aditxt is undergoing major restructuring, including the SPAC listing of subsidiary Ignite Proteomics LLC valued at $150 million and the appointment of Jeffrey M. Busch as interim CEO.
  • The stock trades at $0.01, down 100% year-to-date, despite the company regaining Nasdaq listing compliance through reported stockholders' equity of $3,953,682.

Takeover Time 2026 LLC, identified as a ten percent owner of Aditxt, Inc. (NASDAQ:ADTX), has executed a complete exit from its position, selling 3,420,439 shares of common stock for a total value of $68,408. The transaction was finalized on June 23, 2026, marking the end of the entity's equity stake in the biotechnology firm. This divestiture takes place as the stock trades at a mere $0.01 per share, a figure that represents a catastrophic decline from its 52-week high of $117.84. The stock has posted a -100% return year-to-date, reflecting extreme market pressure and valuation erosion. The shares were disposed of at a price of $0.02 per share during the transaction. Following this sale, Takeover Time 2026 LLC holds no shares of Aditxt common stock. The reporting entity’s managing member, Natasha Ovsepyan, signed the filing, confirming the disposal. InvestingPro data indicates that the stock generally trades with high price volatility and has fared poorly over the last month, among 16 additional ProTips available to subscribers.

The liquidation of the stake coincides with a series of strategic and structural developments at Aditxt. The company announced a significant move involving its subsidiary, Ignite Proteomics LLC, which is set to go public through a special purpose acquisition company (SPAC) deal. This transaction values Ignite at approximately $150 million in implied equity value. In conjunction with this restructuring, Aditxt appointed Jeffrey M. Busch as interim CEO. Busch will continue to lead Ignite Proteomics while simultaneously taking on this new executive role at the parent company.

Further operational adjustments include plans to implement a 1-for-27 reverse stock split, effective May 18, 2026, following approval from stockholders. This corporate action is designed to adjust the share price structure, though it occurs against the backdrop of the recent severe devaluation. Additionally, Aditxt disclosed a $1.25 million private placement of senior unsecured promissory notes. These notes carry an annual interest rate of 10% and mature on September 30, 2026, providing short-term liquidity amidst the restructuring efforts.

Regulatory compliance also played a critical role in the recent corporate narrative. Aditxt announced that it has regained compliance with Nasdaq’s continued listing standards, as confirmed by a letter from The Nasdaq Stock Market LLC. This compliance was achieved after Aditxt reported stockholders’ equity of $3,953,682 in its Annual Report on Form 10-K. These developments mark a period of strategic shifts and financial adjustments for Aditxt, as the company attempts to stabilize its operations while navigating significant equity and structural changes.

Risks

  • The stock's catastrophic decline to $0.01 from a 52-week high of $117.84 indicates extreme volatility and potential liquidity issues for remaining shareholders.
  • The reliance on a $1.25 million private placement of senior unsecured promissory notes with a 10% interest rate highlights potential debt servicing pressures and financial constraints.
  • The execution of a 1-for-27 reverse stock split, while intended to meet listing standards, may further compress the investor base and increase price volatility in the biotechnology sector.

More from Insider Trading

Illumina CLO Divests $110,700 in Equity, Retains Substantial Holdings Amid Strategic Expansion Jun 25, 2026 Stellus Capital Director Arnoult J Tim Accumulates Shares Amid Stock Decline Jun 25, 2026 Clear Secure Executive Unloads $11.3M in Stock Under Pre-Arranged Plan Jun 25, 2026 Clear Secure Director Entity Executes $11.3M Share Sale Under Pre-Arranged Plan Jun 25, 2026 CrowdStrike CEO George Kurtz Executes $2.7M Stock Sale Under Pre-Arranged Plan Jun 25, 2026